We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oncimmune Holdings Plc | LSE:ONC | London | Ordinary Share | GB00BYQ94H38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.20 | 0.95% | 21.20 | 20.60 | 22.00 | 21.00 | 21.00 | 21.00 | 12,949 | 16:35:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 1.47M | -6.15M | -0.0830 | -2.53 | 15.57M |
TIDMONC
RNS Number : 6285W
Oncimmune Holdings PLC
16 November 2017
16 November 2017
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Distribution agreement signed for EarlyCDT(R)-Lung Kit in Iran
Agreement for screening and indeterminate pulmonary nodule applications with minimum sales commitment of approximately GBP1.1m
Nottingham, UK - 9 November 2017: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, today announces it has signed an exclusive agreement for distribution of its EarlyCDT(R)-Lung test in Iran with Tarvand Sina Tajhiz Co., an Iranian provider of test services and kits to the medical community.
The agreement allows for the sale of the CE marked EarlyCDT(R)-Lung kit as a screening test and for the risk assessment of indeterminate pulmonary nodules. The agreement is for an initial term of three years and includes minimum sales commitments of GBP1.1 million over the term of the contract. First sales are expected to commence in the second half of 2018.
Geoffrey Hamilton-Fairley, CEO of Oncimmune, commented: "This distribution agreement is our seventh in the Asia Pacific region and now brings the minimum sales commitment in this region to approximately GBP7.6 million over the next five years. In the coming months we expect to sign a number of further agreements in the region, and beyond, as we continue to deliver on our strategy of generating revenues from our platform technology through multiple products, regions and partners."
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Advisor and Broker)
Giles Balleny, Hugh Kingsmill Moore
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
About Oncimmune
Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT(R)-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT(R)-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT(R)-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT(R) tests for liver and ovarian cancer are in development.
Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRGGGAWGUPMGQA
(END) Dow Jones Newswires
November 16, 2017 02:00 ET (07:00 GMT)
1 Year Oncimmune Chart |
1 Month Oncimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions